胰腺癌手术切除后辅助吉西他滨联合S-1化疗
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
作者信息
Murakami Yoshiaki, Uemura Kenichiro, Sudo Takeshi, Hayashidani Yasuo, Hashimoto Yasushi, Nakagawa Naoya, Ohge Hiroki, Sueda Taijiro
机构信息
Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
出版信息
Am J Surg. 2008 Jun;195(6):757-62. doi: 10.1016/j.amjsurg.2007.04.018.
BACKGROUND
The aim of this study was to determine the effectiveness of adjuvant gemcitabine plus S-1 chemotherapy for patients with pancreatic carcinoma.
METHODS
Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks. Each chemotherapy cycle consisted of intravenous gemcitabine, 700 mg/m(2), on day 1 and orally administered S-1, 50 mg/m(2), for 7 consecutive days, after which there was a 1-week pause of chemotherapy.
RESULTS
Twenty-seven patients were entered into this study. According to the TNM system, 4 (15%), 2 (7%), 6 (22%), and 15 (56%) patients were diagnosed with stage IA, IB, IIA, and IIB disease, respectively. Overall and disease-free survival rates were 86% and 60% at 1 year, 66% and 45% at 2 years, and 33% and 45% at 3 years, respectively. Toxicity during chemotherapy was mild.
CONCLUSIONS
Adjuvant gemcitabine plus S-1 chemotherapy appears to be a promising treatment for patients after surgical resection of pancreatic adenocarcinoma.
背景
本研究旨在确定吉西他滨联合S-1辅助化疗对胰腺癌患者的有效性。
方法
因胰腺腺癌接受根治性手术的患者每2周接受10个周期的吉西他滨联合S-1辅助化疗。每个化疗周期包括第1天静脉注射吉西他滨700mg/m²，以及连续7天口服S-1 50mg/m²，之后化疗暂停1周。
结果
27例患者纳入本研究。根据TNM系统，分别有4例（15%）、2例（7%）、6例（22%）和15例（56%）患者被诊断为IA期、IB期、IIA期和IIB期疾病。1年时总生存率和无病生存率分别为86%和60%，2年时分别为66%和45%，3年时分别为33%和45%。化疗期间毒性轻微。
结论
辅助性吉西他滨联合S-1化疗似乎是胰腺腺癌手术切除术后患者的一种有前景的治疗方法。
Zotero 插件